Amid an al­ready slow roll­out, Bio­gen's Aduhelm could soon face price com­pe­ti­tion — re­port

De­spite the snail-paced roll­out of Bio­gen’s con­tro­ver­sial­ly ap­proved Alzheimer’s treat­ment Aduhelm, CEO Michel Vounatsos in­sist­ed on the lat­est earn­ings call that he’s con­fi­dent in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER